Immunoassay Blocking (BSA Free) (ab171535)
Overview
-
Product name
Immunoassay Blocking (BSA Free) -
Tested applications
Suitable for: ELISAmore details
Unsuitable for: IHC-Fr or IHC-P -
General notes
Abcam’s Immunoassay Blocking (BSA Free) (ab171535) maintains the activity of antibodies and other biomolecules adsorbed or immobilized to solid substrates. It is easily incorporated into most assay protocols as the blocking solution, and minimal incubation is required. For blocking nonspecific sites on hydrophobic substrates, incubate for as little as five minutes and then proceed with your assay. Longer incubation times, while not necessary, are also not detrimental. For simultaneous blocking and stabilizing, apply ab171535 and incubate. Remove excess solution and completely dry the component. For maximum shelf life, store the stabilized component in a sealed container with desiccant.
To Stabilize Adsorbed or Immobilized Proteins on Microtiter Plates/Strips
1. For optimal stability and performance, use ab171535 at 100% concentration
2. Immobilize or adsorb the primary protein (antibody or antigen) according to the procedure optimized in your laboratory; wash adequately to remove excess or weakly bound material
3. Immediately after washing, add ab171535 to allow interaction with the entire protein-coated surface; do not let coated components dry before adding ab171535 since drying contributes to the loss of protein activity
4. Incubate for five minutes to two hours at room temperature; for most assays, ab171535 can replace the blocking solution
5. Remove or aspirate ab171535, but do not wash
6. To dry components for long-term storage, we recommend one of the following methods:– Option 1. Place plates in a humidity-controlled chamber until dry (2-24 hours)
– Option 2. Dry 2 -24 hours in a sealed desiccated container, such as a cabinet, jar, or plastic bag containing calcium sulfate or silica gel desiccant in amounts adequate for the size of the container, or
– Option 3. Dry plates at 30°C-40°C in a vacuum oven for 2-4 hoursNOTE: Drying times should be optimized for each application
7. Immediately package the dried product in an airtight, moisture-proof container with a desiccant; this is especially important with the final product is stored in a humid environment or refrigerated where condensation is likely to occur
Properties
-
Form
Liquid -
Storage instructions
Store at room temperature. -
Storage buffer
pH: 7
Constituent: 100% Proprietary component
pH 6.6 - 7.2. Preservative: None. -
Concentration information loading...
Associated products
-
Related Products
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab171535 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
ELISA |
Use at an assay dependent concentration.
|
Notes |
---|
ELISA
Use at an assay dependent concentration. |
Images
-
Stability tests were performed with Immunoassay Blocking (BSA Free) (ab171535) using either monoclonal or polyclonal IgG antibodies.
Coated microtiter plates were stabilized with either ab171535 or 1% BSA. The antibody-coated plates were dried and placed at room temperature. Percent retained activity was determined by comparing the activity of the aged antibody-coated microtiter plates to that of freshly coated plates.
After 30 months in Immunoassay Blocking (BSA Free) (ab171535) at room temperature, the monoclonal antibody retained greater than 85% activity and the polyclonal antibody retained 90% activity.
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
References (6)
ab171535 has been referenced in 6 publications.
- Cao J et al. Matrine has pro-apoptotic effects on liver cancer by triggering mitochondrial fission and activating Mst1-JNK signalling pathways. J Physiol Sci 69:185-198 (2019). PubMed: 30155612
- Li J et al. Liraglutide protects renal mesangial cells against hyperglycemia-mediated mitochondrial apoptosis by activating the ERK-Yap signaling pathway and upregulating Sirt3 expression. Mol Med Rep 19:2849-2860 (2019). PubMed: 30816450
- Wang Y et al. Sirt3-mediated mitochondrial fission regulates the colorectal cancer stress response by modulating the Akt/PTEN signalling pathway. Biomed Pharmacother 105:1172-1182 (2018). PubMed: 30021354
- Ji K et al. TAZ inhibition promotes IL-2-induced apoptosis of hepatocellular carcinoma cells by activating the JNK/F-actin/mitochondrial fission pathway. Cancer Cell Int 18:117 (2018). PubMed: 30127666
- Wei R et al. Matrine promotes liver cancer cell apoptosis by inhibiting mitophagy and PINK1/Parkin pathways. Cell Stress Chaperones 23:1295-1309 (2018). PubMed: 30209783
- Bossi F et al. Systematic discovery of novel eukaryotic transcriptional regulators using sequence homology independent prediction. BMC Genomics 18:480 (2017). PubMed: 28651538